isatuximab-话题@MedSci

#isatuximab#

8篇内容 | 1366人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2192245, encodeId=b9722192245de, content=<a href='/topic/show?id=8e0d10065ff' target=_blank style='color:#2F92EE;'>#isatuximab#</a> <a href='/topic/show?id=c34d64e47d1' target=_blank style='color:#2F92EE;'>#泊马度胺#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=79f9112091aa' target=_blank style='color:#2F92EE;'>#难治性多发性骨髓瘤#</a>, objectTitle=【血液学】Isatuximab+泊马度胺+地塞米松治疗RRMM的3期研究最终OS结果, objectType=article, longId=816538, objectId=d333816538ff, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, objectUrl=/article/show_article.do?id=d333816538ff, replyNumber=0, likeNumber=96, createdTime=2024-03-09, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d333816538ff, moduleTitle=【血液学】Isatuximab+泊马度胺+地塞米松治疗RRMM的3期研究最终OS结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d333816538ff)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1422633, encodeId=b2c81422633ab, content=<a href='/topic/show?id=8e0d10065ff' target=_blank style='color:#2F92EE;'>#isatuximab#</a>, objectTitle=Lancet Oncol：泊马度胺-地塞米松方案加用Isatuximab可显著延长复发/难治性多发性骨髓瘤患者的总生存期, objectType=article, longId=295593, objectId=ab9629559335, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab9629559335, replyNumber=0, likeNumber=92, createdTime=2022-02-15, rootId=0, userName=qingrejiedu, userId=e5fc3724043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab9629559335, moduleTitle=Lancet Oncol：泊马度胺-地塞米松方案加用Isatuximab可显著延长复发/难治性多发性骨髓瘤患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab9629559335)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422632, encodeId=b1021422632d8, content=<a href='/topic/show?id=8e0d10065ff' target=_blank style='color:#2F92EE;'>#isatuximab#</a>, objectTitle=Haematologica：Isatuximab 加卡非佐米和地塞米松与卡非佐米和地塞米松在肾功能不全的复发性多发性骨髓瘤患者中的比较, objectType=article, longId=292200, objectId=8c42292200d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c42292200d9, replyNumber=0, likeNumber=64, createdTime=2021-12-20, rootId=0, userName=qingrejiedu, userId=e5fc3724043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c42292200d9, moduleTitle=Haematologica：Isatuximab 加卡非佐米和地塞米松与卡非佐米和地塞米松在肾功能不全的复发性多发性骨髓瘤患者中的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c42292200d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422631, encodeId=1c23142263120, content=<a href='/topic/show?id=8e0d10065ff' target=_blank style='color:#2F92EE;'>#isatuximab#</a>, objectTitle=BLOOD：好消息！ISAtuximab 联合地塞米松治疗复发/难治性多发性骨髓瘤可提高ORR, objectType=article, longId=207913, objectId=49ca20e9132b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49ca20e9132b, replyNumber=0, likeNumber=77, createdTime=2021-03-07, rootId=0, userName=qingrejiedu, userId=e5fc3724043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49ca20e9132b, moduleTitle=BLOOD：好消息！ISAtuximab 联合地塞米松治疗复发/难治性多发性骨髓瘤可提高ORR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49ca20e9132b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422630, encodeId=a1321422630fd, content=<a href='/topic/show?id=8e0d10065ff' target=_blank style='color:#2F92EE;'>#isatuximab#</a>, objectTitle=CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤, objectType=article, longId=207705, objectId=73c620e7058a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73c620e7058a, replyNumber=0, likeNumber=68, createdTime=2021-03-01, rootId=0, userName=qingrejiedu, userId=e5fc3724043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73c620e7058a, moduleTitle=CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73c620e7058a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422629, encodeId=49f7142262933, content=<a href='/topic/show?id=8e0d10065ff' target=_blank style='color:#2F92EE;'>#isatuximab#</a>, objectTitle=NICE指南支持isatuximab治疗多发性骨髓瘤（MM）, objectType=article, longId=203866, objectId=3f4520386600, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f4520386600, replyNumber=0, likeNumber=123, createdTime=2020-12-01, rootId=0, userName=qingrejiedu, userId=e5fc3724043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f4520386600, moduleTitle=NICE指南支持isatuximab治疗多发性骨髓瘤（MM）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f4520386600)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422628, encodeId=c0761422628e1, content=<a href='/topic/show?id=8e0d10065ff' target=_blank style='color:#2F92EE;'>#isatuximab#</a>, objectTitle=Blood：Isatuximab±地塞米松治疗复发/难治性多发性骨髓瘤, objectType=article, longId=202717, objectId=e79a202e1700, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e79a202e1700, replyNumber=0, likeNumber=117, createdTime=2020-11-02, rootId=0, userName=qingrejiedu, userId=e5fc3724043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e79a202e1700, moduleTitle=Blood：Isatuximab±地塞米松治疗复发/难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e79a202e1700)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422627, encodeId=68ff142262e30, content=<a href='/topic/show?id=8e0d10065ff' target=_blank style='color:#2F92EE;'>#isatuximab#</a>, objectTitle=Lancet：Isatuximab、Pomalidomide联合地塞米松治疗复发难治性MM, objectType=article, longId=183068, objectId=6a8f1830682e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a8f1830682e, replyNumber=0, likeNumber=82, createdTime=2019-11-17, rootId=0, userName=qingrejiedu, userId=e5fc3724043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a8f1830682e, moduleTitle=Lancet：Isatuximab、Pomalidomide联合地塞米松治疗复发难治性MM, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a8f1830682e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422626, encodeId=1fae14226262d, content=<a href='/topic/show?id=8e0d10065ff' target=_blank style='color:#2F92EE;'>#isatuximab#</a>, objectTitle=FDA接受了赛诺菲的申请，要求批准isatuximab用于复发难治多发性骨髓瘤患者, objectType=article, longId=175274, objectId=fe9b1e5274cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe9b1e5274cc, replyNumber=0, likeNumber=65, createdTime=2019-07-13, rootId=0, userName=qingrejiedu, userId=e5fc3724043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe9b1e5274cc, moduleTitle=FDA接受了赛诺菲的申请，要求批准isatuximab用于复发难治多发性骨髓瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe9b1e5274cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

isatuximab

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#isatuximab# #泊马度胺# #地塞米松# #难治性多发性骨髓瘤#

【血液学】Isatuximab+泊马度胺+地塞米松治疗RRMM的3期研究最终OS结果

2024-03-09发表于上海

qingrejiedu (审核中...)

前往app查看评论内容

#isatuximab#

Lancet Oncol：泊马度胺-地塞米松方案加用Isatuximab可显著延长复发/难治性多发性骨髓瘤患者的总生存期

2022-02-15

qingrejiedu (审核中...)

前往app查看评论内容

#isatuximab#

Haematologica：Isatuximab 加卡非佐米和地塞米松与卡非佐米和地塞米松在肾功能不全的复发性多发性骨髓瘤患者中的比较

2021-12-20

qingrejiedu (审核中...)

前往app查看评论内容

#isatuximab#

BLOOD：好消息！ISAtuximab 联合地塞米松治疗复发/难治性多发性骨髓瘤可提高ORR

2021-03-07

qingrejiedu (审核中...)

前往app查看评论内容

#isatuximab#

CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤

2021-03-01

qingrejiedu (审核中...)

前往app查看评论内容

#isatuximab#

NICE指南支持isatuximab治疗多发性骨髓瘤（MM）

2020-12-01

qingrejiedu (审核中...)

前往app查看评论内容

#isatuximab#

Blood：Isatuximab±地塞米松治疗复发/难治性多发性骨髓瘤

2020-11-02

qingrejiedu (审核中...)

前往app查看评论内容

#isatuximab#

Lancet：Isatuximab、Pomalidomide联合地塞米松治疗复发难治性MM

2019-11-17

qingrejiedu (审核中...)

前往app查看评论内容

#isatuximab#

FDA接受了赛诺菲的申请，要求批准isatuximab用于复发难治多发性骨髓瘤患者

2019-07-13

科室
- - 订阅+
  - 更多科室
工具
服务